Erica Collins
Nurse Practitioner · Dallas, TXNPI 1780980029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,175 and has fallen 71.6% since, to $333 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$583
- Amgen$573
- Veloxis Pharmaceuticals, Inc.$303
- Takeda Pharmaceuticals U.S.A., Inc.$283
- Aurinia Pharma U.S., Inc.$234
- Merck$227
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,698100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $583 |
| Amgen(2 entities) | 23 | $573 |
| Veloxis Pharmaceuticals, Inc. | 10 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $283 |
| Aurinia Pharma U.S., Inc. | 11 | $234 |
| Merck | 10 | $227 |
| Mallinckrodt Hospital Products Inc. | 7 | $159 |
| Cormedix Inc. | 6 | $155 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Amarin Pharma, Inc. | 8 | $136 |
| Vifor Pharma, Inc. | 6 | $130 |
| Novo Nordisk | 6 | $128 |
| Shield Therapeutics Inc | 2 | $86 |
| Bayer | 3 | $63 |
| Lilly USA, LLC | 3 | $53 |
| Eurofins Viracor, LLC | 1 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Boehringer Ingelheim | 2 | $36 |
| Travere Therapeutics, Inc. | 3 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Pfizer | 2 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Sanofi | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| GSK | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$3,699 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Dallas
- Samantha OnealDallas$133K
- Tam TranDallas$37K
- Tobin SpeightDallas$35K
- Rachel TiuDallas$19K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.